Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24193187 | 0.94 | MDM2 (0.42) | MDM2TLR2TLR1KMT2A | |
| SCHEMBL24193189 | 0.90 | MDM2 (0.55) | MDM2SIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL21963412 | 0.90 | MDM2 (0.55) | MDM2SIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL22021730 | 0.90 | TLR2 (0.41) | MDM2SIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL24193273 | 0.87 | MDM2 (0.55) | MDM2SIRT2SIRT1TLR2KMT2A | |
| SCHEMBL21963477 | 0.84 | MDM2 (0.42) | MDM2SIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL21963478 | 0.84 | MDM2 (0.42) | MDM2SIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL30783495 | 0.83 | TLR2 (0.54) | MDM2TLR2TLR1KMT2A | |
| SCHEMBL27261267 | 0.83 | TLR2 (0.54) | MDM2TLR2TLR1KMT2A | |
| SCHEMBL22021738 | 0.83 | MDM2 (0.56) | MDM2SIRT2SIRT1TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2020102348-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | DIMAGNO STEPHEN (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | ALB, TTR, ABCG2 | MDM2 1543/4885SIRT2 1770/4885SIRT1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.